Core Clinical Molecular Diagnostics Market to Grow with a CAGR of 9.89% through 2030
The increasing
demand for personalized medicine and the advancements in next-generation
sequencing technologies, is expected to drive the Global Core Clinical
Molecular Diagnostics Market growth in the forecast period, 2026-2030
According to
TechSci Research report, “Core Clinical Molecular Diagnostics Market –
Global Industry Size, Share, Trends, Competition Forecast &
Opportunities, 2030F”, the Global Core Clinical Molecular Diagnostics
Market stood at USD 6.48
Billion in 2024 and is expected to reach USD 11.43 Billion by
2030 with a CAGR of 9.89% during the forecast period. The clinical molecular
diagnostics market is gaining momentum due to the growing demand for precision
medicine and advancements in diagnostic technologies. Innovations in DNA/RNA
testing, proteomics, and immunohistochemistry are reshaping the diagnostic landscape,
enabling more accurate identification of genetic variations, disease-causing
pathogens, and tumor markers. These advances have facilitated earlier and more
targeted interventions, leading to improved patient outcomes. The shift towards
personalized medicine, where treatment regimens are tailored to individual
genetic profiles, is propelling the adoption of molecular diagnostic tests, as
they provide valuable insights that optimize therapy decisions and patient
management.
Technological
advancements, such as the introduction of high-throughput sequencing
technologies and microarray-based platforms, have transformed the way diseases
are detected and monitored. These innovations allow for comprehensive genomic
profiling, improving the detection of rare diseases and the monitoring of
chronic conditions. The increasing integration of artificial intelligence and
machine learning in diagnostic tools further enhances the capabilities of
molecular diagnostics by automating data interpretation, reducing human error,
and enabling faster results. This growing technological sophistication is
making molecular diagnostics more efficient and accessible, further driving
their adoption in both clinical and research settings.
The clinical
molecular diagnostics market also presents a range of growth opportunities. The
development of point-of-care molecular diagnostic devices is one such
opportunity, as these portable, user-friendly devices can provide rapid,
on-site results, especially in resource-limited environments. The expansion of
molecular diagnostics in emerging markets presents another key opportunity,
driven by rising healthcare investments and improving healthcare infrastructure
in these regions. Furthermore, the increasing demand for companion diagnostics,
which helps identify patients who would benefit from specific targeted
therapies, is fueling the market. As the industry continues to evolve,
partnerships between technology developers, diagnostic manufacturers, and
pharmaceutical companies are expected to drive innovation and accelerate the
global adoption of molecular diagnostics.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Core Clinical Molecular Diagnostics Market”
The Global Core
Clinical Molecular Diagnostics Market is segmented into product type,
technology, application, end user, regional distribution, and company.
Based on the Technology,
Nucleic Acid Sequencing emerged as the fastest growing segment in the Global Core
Clinical Molecular Diagnostics Market during the forecast period. This is due
to its transformative capabilities in genomic analysis. NGS enables
comprehensive and high-throughput analysis of DNA and RNA, allowing for the
detection of genetic mutations, variations, and biomarkers that are critical
for diagnosing a wide range of diseases, including cancer, genetic disorders,
and infectious diseases. This technology provides far more detailed and precise
insights compared to traditional methods, such as PCR, making it highly
valuable in personalized medicine and targeted therapies. The decreasing cost
of sequencing and the improvements in speed, accuracy, and efficiency have made
NGS more accessible and attractive to clinical laboratories and healthcare
providers. The ability to analyze entire genomes, exomes, or transcriptomes in a
single test is driving its adoption, particularly in oncology for identifying
genetic mutations and biomarkers that guide treatment decisions. As the demand
for precision medicine grows, NGS is increasingly being used for disease
prevention, early detection, and monitoring treatment responses.
Based
on the Region, Asia-Pacific emerged as the fastest growing region in the Global
Core Clinical Molecular Diagnostics Market during the forecast period. This is due to several key
factors driving its rapid expansion. One of the primary reasons is the growing
demand for advanced diagnostic solutions, particularly in countries like China,
India, Japan, and South Korea, where healthcare infrastructure is improving and
the prevalence of chronic diseases, infectious diseases, and cancer is rising.
As these countries focus on enhancing their healthcare systems, there is an
increasing push towards the adoption of molecular diagnostics to enable more
accurate and timely diagnoses. The region is also experiencing significant
investments in healthcare and biotechnology, with both public and private
sectors supporting the development and implementation of cutting-edge
diagnostic technologies. Additionally, the growing awareness of personalized
medicine and genetic testing in countries like Japan and India is fueling the
demand for molecular diagnostic tools. Moreover, advancements in research,
rising healthcare expenditures, and government initiatives aimed at improving
access to healthcare are contributing to the adoption of molecular diagnostics
across the region.
Asia-Pacific
also benefits from the increasing availability of affordable molecular
diagnostic technologies and growing collaborations between global and local
companies. As the region's healthcare systems evolve, the demand for innovative
and efficient diagnostic solutions, such as PCR, NGS, and liquid biopsy, is set
to drive sustained growth in the coming years.
Major
companies operating in Global Core Clinical Molecular Diagnostics Market
are:
- F.
Hoffmann-La Roche Ltd.
- Danaher
Corporation
- Abbott
Laboratories
- Thermo
Fisher Scientific Inc.
- QIAGEN
N.V.
- Hologic
Inc.
- bioMérieux
SA
- Siemens
Healthineers AG
- Becton,
Dickinson and Company
- Agilent
Technologies, Inc.
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Global Core Clinical Molecular
Diagnostics Market is expanding due to the increasing investments in research
and development by pharmaceutical and biotechnology companies, driving
innovations in molecular diagnostic technologies. These investments are
accelerating the development of novel diagnostic solutions, particularly for
complex diseases like cancer, genetic disorders, and infectious diseases. As
the demand for faster, more accurate, and less invasive diagnostic methods
grows, the focus on improving the efficiency of molecular diagnostics through
the integration of artificial intelligence and machine learning for data
analysis is further propelling market growth. These technological advancements
are enhancing the precision of diagnostics and enabling quicker decision-making
in clinical settings.,” said Mr. Karan Chechi, Research Director of TechSci
Research, a research-based management consulting firm.
“Core Clinical Molecular
Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, Segmented By Product Type (Instruments, Reagents & Kits, Software
& Services), By Technology (PCR, Nucleic Acid Sequencing, Fluorescence In
Situ Hybridization (FISH), Others), By Application (Infectious Disease, Genetic
Disorder, Cancer Screening, Others), By End User (Hospitals & Diagnostic
Laboratories, Academic & Research Institutions, Pharmaceutical &
Biotechnology Companies, Contract Research Organizations (CROs), Others), By
Region and Competition, 2020-2030F”, has evaluated the future growth
potential of Global Core Clinical Molecular Diagnostics Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Core Clinical Molecular Diagnostics
Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com